A
Apertura Gene Therapy
Leverages ML to engineer novel capsids, gene regulatory elements to simultaneously enhance gene therapies
About Apertura Gene Therapy
Apertura GTX is a pioneering startup in the field of gene therapy, focusing on treating a broad range of diseases that currently have limited treatment options. The company operates in the biotechnology market, specifically in the niche of genetic medicine. It is uniquely positioned to develop these genetic treatments by engineering AAV capsids, regulatory elements, and payloads simultaneously.
The company's business model is centered around overcoming the current limitations of AAV gene therapy, which include issues in cellular access, gene expression, pre-existing immunity, and manufacturability. Apertura GTX leverages recent advances in vector biology, protein engineering, machine learning, epigenetic profiling, next-generation sequencing, and DNA synthesis to address these challenges.
Apertura GTX's clients are primarily patients suffering from rare genetic disorders. The company is also open to collaborations with corporate and academic partners, as well as disease foundations, to maximize its impact and accelerate the development of transformative gene therapies.
The company generates revenue by developing and selling gene therapies. It also potentially earns income through strategic partnerships and collaborations.
In summary, Apertura GTX is a biotech startup that is pushing the boundaries of gene therapy to treat a wider range of diseases. It uses a multidisciplinary approach, combining advances in various scientific fields, to overcome the current limitations of gene therapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- New York City, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 32.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Spinout, Biotech and Pharma, AI Applications, proteomics, DT and LS, science-based
- Technology
- Artificial Intelligence, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2022 | $67M | $268M | Deerfield | ↗ |
| SPINOUTOther financing | Jan 2021 | $0 | — | Massachusetts Institute of Technology · Harvard University | — |
Growth signals
Latest recorded traffic for Apertura Gene Therapy is 3.5K monthly website visits, up 45.8% over the last three months. Apertura Gene Therapy's team declined 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Deerfield
Other known investors2 additional known investors
Harvard University
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Apertura Gene Therapy on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apertura Gene Therapy’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.